Bloomberg News Health Reporter Madison Muller discusses how the drug Ozempic could cut demand for big-money drugs targeting a wide range of maladies, even Alzheimer’s. 
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.

Bloomberg News Health Reporter Madison Muller discusses how the drug <a href="https://www.bloomberg.com/news/articles/2023-10-04/walmart-says-ozempic-weight-loss-drugs-causing-slight-pullback-by-shoppers">Ozempic</a> could <a href="https://www.bloomberg.com/news/newsletters/2023-10-18/ozempic-mounjaro-and-glp-1s-alternate-uses-and-drugmaker-implications">cut demand for big-money drugs</a> targeting a wide range of maladies, even Alzheimer’s. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

Ozempic’s Success Is Bad News for Rivals

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/9ef3edc7-4472-4ff3-96e2-b0a400c9e70d/transcript

Advertisement